To enable the early detection of atrial fibrillation and subsequent intervention, Mehiläinen and CardioSignal are collaborating to build a digital health approach that includes offering home monitoring to at-risk individuals in Finland. Early detection of atrial fibrillation has the potential to significantly reduce future hospitalizations from heart failure or stroke.

The collaboration includes making easy-to-use, at-home monitoring of atrial fibrillation available for at-risk individuals in France through a network of 1,000 cardiologists. The initiative aims to reach 5,000 individuals to prevent adverse health outcomes caused by undiagnosed atrial fibrillation.

With this collaboration, CardioSignal’s motion sensor technology for heart disease detection is made available for healthcare professionals by combining it with Roche’s blood glucometer.

With a large population with over half a billion smartphone users and growing demand for at-home solutions in heart health monitoring, India is the next natural step in CardioSignal’s global expansion.

As the Chief Medical Officer and General Manager of US operations, Dr. Alastalo brings CardioSignal expertise, access and a strong track record to establishing operations in the United States.

CardioSignal is developing a disruptive mobile application-based technology to improve the detection of heart disease. Utilizing sensitive motion sensors in modern smartphones, the CardioSignal application detects heart motion with high accuracy.